Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	5.39	2.93	8.31	-14.93	-27.58	-6.52
Depreciation & Amortization	1.41	1.3	1.19	1.09	1.12	1.3
Stock-Based Compensation	2.22	3.25	3.45	2.09	2.38	3.13
Other Adjustments	-0.08	0.37	-3.73	-1.23	3.9	3.12
Change in Receivables	-12.52	2.32	-0.43	-1.19	-1.03	2.09
Changes in Inventories	-4.06	-2.2	-2.24	1.15	-4.87	-4.93
Changes in Accounts Payable	-2.67	0.7	5.3	-4.8	2.39	2.27
Changes in Unearned Revenue	-6.35	-	-13.18	-7.16	13.23	-26.21
Changes in Other Operating Activities	-0.08	-0	0.01	-0.01	0.19	-0.36
Operating Cash Flow	-10.03	8.67	-1.32	-25	-10.29	-26.11
Capital Expenditures	-1.66	-1.28	-1.15	-0.63	-1.46	-0.66
Sale of Property, Plant & Equipment	-	0	-	-	0.05	-
Purchases of Investments	-	-15	-20.42	-16	-37.84	-20
Proceeds from Sale of Investments	-	20.42	5	11	57.84	-
Other Investing Activities	0.09	0.08	-0.14	0.59	0.33	0.7
Investing Cash Flow	-16.57	4.22	-16.71	-5.04	18.92	-19.95
Long-Term Debt Repaid	-	-20.42	-	-	-34.12	-0.22
Net Long-Term Debt Issued (Repaid)	-	-20.42	-	-	-34.12	-0.22
Issuance of Common Stock	12.81	3.63	24.67	8.24	46.2	46.68
Net Common Stock Issued (Repurchased)	12.81	3.63	24.67	8.24	46.2	46.68
Financing Cash Flow	12.81	-16.79	24.67	8.24	12.08	46.47
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.04	0.03	-0.11	-0.08	0.01	0.06
Net Cash Flow	-13.76	-3.87	6.52	-21.87	20.72	0.47
Free Cash Flow	-11.69	7.39	-2.47	-25.63	-11.74	-26.76
FCF Margin	-18.91%	13.84%	-3.77%	-53.80%	-30.62%	-42.55%
Free Cash Flow Per Share	-0.14	0.09	-0.03	-0.53	-0.27	-0.92
Levered Free Cash Flow	-8	-18.97	-1.76	-25.29	-51.11	-35.31
Unlevered Free Cash Flow	-7.46	1.34	-0.01	-23.81	-9.87	-25.86

Updated Nov 13, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q